Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma

Yuko Kono, Olivier Lucidarme, Sang Hee Choi, Steven C. Rose, Tarek I. Hassanein, Elliot Alpert, Robert F. Mattrey

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: To determine whether contrast-enhanced ultrasound (CEUS) can aid in assessing treatment efficacy within the first 2 weeks after transarterial chemoembolization for hepatocellular carcinoma. Materials and methods: Contrast-enhanced ultrasound was performed to detect residual tumor blood flow after 42 transarterial chemoembolization procedures in 33 patients who had hepatocellular carcinomas, and the results were compared with final tumor outcome. Twenty-nine CEUS studies were performed within 2 weeks after treatment and the remainder within 1 month. Phase-inversion low-mechanical-index real-time and intermittent imaging were performed after the intravenous injection of 0.5-2 mL US contrast medium by experienced radiologists blind to all other imaging findings. Results: Nine tumors did not reach final outcome-patients were lost to follow-up or died without autopsy (n = 6) or tumors were retreated before final outcome was established (n = 3). Of the remaining 33 tumors, outcome was established by histology (n = 9), angiography (n = 14), tumor growth (n = 2), or by computed tomography and/or magnetic resonance imaging performed more than 6 months after treatment (n = 8). Twenty-three tumors were studied by CEUS within 2 weeks and 10 within 1 month after treatment. Of these 33 tumors, there were no false-negative results and one false-positive result. The only error occurred when the CEUS study was performed within 1 day after treatment. Conclusions: Residual tumor blood flow on CEUS performed at 2 or more days after transarterial chemoembolization may be predictive of tumor outcome that currently requires 3 months to be reliably detected by computed tomography and/or magnetic resonance imaging.

Original languageEnglish (US)
Pages (from-to)57-65
Number of pages9
JournalJournal of Vascular and Interventional Radiology
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Residual Neoplasm
Contrast Media
Tomography
Magnetic Resonance Imaging
Lost to Follow-Up
Therapeutics
Intravenous Injections
Autopsy
Histology
Angiography
Growth

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma. / Kono, Yuko; Lucidarme, Olivier; Choi, Sang Hee; Rose, Steven C.; Hassanein, Tarek I.; Alpert, Elliot; Mattrey, Robert F.

In: Journal of Vascular and Interventional Radiology, Vol. 18, No. 1, 01.01.2007, p. 57-65.

Research output: Contribution to journalArticle

Kono, Yuko ; Lucidarme, Olivier ; Choi, Sang Hee ; Rose, Steven C. ; Hassanein, Tarek I. ; Alpert, Elliot ; Mattrey, Robert F. / Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma. In: Journal of Vascular and Interventional Radiology. 2007 ; Vol. 18, No. 1. pp. 57-65.
@article{a772cbdda3a34cf4806176fcd0cea416,
title = "Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma",
abstract = "Purpose: To determine whether contrast-enhanced ultrasound (CEUS) can aid in assessing treatment efficacy within the first 2 weeks after transarterial chemoembolization for hepatocellular carcinoma. Materials and methods: Contrast-enhanced ultrasound was performed to detect residual tumor blood flow after 42 transarterial chemoembolization procedures in 33 patients who had hepatocellular carcinomas, and the results were compared with final tumor outcome. Twenty-nine CEUS studies were performed within 2 weeks after treatment and the remainder within 1 month. Phase-inversion low-mechanical-index real-time and intermittent imaging were performed after the intravenous injection of 0.5-2 mL US contrast medium by experienced radiologists blind to all other imaging findings. Results: Nine tumors did not reach final outcome-patients were lost to follow-up or died without autopsy (n = 6) or tumors were retreated before final outcome was established (n = 3). Of the remaining 33 tumors, outcome was established by histology (n = 9), angiography (n = 14), tumor growth (n = 2), or by computed tomography and/or magnetic resonance imaging performed more than 6 months after treatment (n = 8). Twenty-three tumors were studied by CEUS within 2 weeks and 10 within 1 month after treatment. Of these 33 tumors, there were no false-negative results and one false-positive result. The only error occurred when the CEUS study was performed within 1 day after treatment. Conclusions: Residual tumor blood flow on CEUS performed at 2 or more days after transarterial chemoembolization may be predictive of tumor outcome that currently requires 3 months to be reliably detected by computed tomography and/or magnetic resonance imaging.",
author = "Yuko Kono and Olivier Lucidarme and Choi, {Sang Hee} and Rose, {Steven C.} and Hassanein, {Tarek I.} and Elliot Alpert and Mattrey, {Robert F.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/j.jvir.2006.10.016",
language = "English (US)",
volume = "18",
pages = "57--65",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Contrast-enhanced Ultrasound as a Predictor of Treatment Efficacy within 2 Weeks after Transarterial Chemoembolization of Hepatocellular Carcinoma

AU - Kono, Yuko

AU - Lucidarme, Olivier

AU - Choi, Sang Hee

AU - Rose, Steven C.

AU - Hassanein, Tarek I.

AU - Alpert, Elliot

AU - Mattrey, Robert F.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Purpose: To determine whether contrast-enhanced ultrasound (CEUS) can aid in assessing treatment efficacy within the first 2 weeks after transarterial chemoembolization for hepatocellular carcinoma. Materials and methods: Contrast-enhanced ultrasound was performed to detect residual tumor blood flow after 42 transarterial chemoembolization procedures in 33 patients who had hepatocellular carcinomas, and the results were compared with final tumor outcome. Twenty-nine CEUS studies were performed within 2 weeks after treatment and the remainder within 1 month. Phase-inversion low-mechanical-index real-time and intermittent imaging were performed after the intravenous injection of 0.5-2 mL US contrast medium by experienced radiologists blind to all other imaging findings. Results: Nine tumors did not reach final outcome-patients were lost to follow-up or died without autopsy (n = 6) or tumors were retreated before final outcome was established (n = 3). Of the remaining 33 tumors, outcome was established by histology (n = 9), angiography (n = 14), tumor growth (n = 2), or by computed tomography and/or magnetic resonance imaging performed more than 6 months after treatment (n = 8). Twenty-three tumors were studied by CEUS within 2 weeks and 10 within 1 month after treatment. Of these 33 tumors, there were no false-negative results and one false-positive result. The only error occurred when the CEUS study was performed within 1 day after treatment. Conclusions: Residual tumor blood flow on CEUS performed at 2 or more days after transarterial chemoembolization may be predictive of tumor outcome that currently requires 3 months to be reliably detected by computed tomography and/or magnetic resonance imaging.

AB - Purpose: To determine whether contrast-enhanced ultrasound (CEUS) can aid in assessing treatment efficacy within the first 2 weeks after transarterial chemoembolization for hepatocellular carcinoma. Materials and methods: Contrast-enhanced ultrasound was performed to detect residual tumor blood flow after 42 transarterial chemoembolization procedures in 33 patients who had hepatocellular carcinomas, and the results were compared with final tumor outcome. Twenty-nine CEUS studies were performed within 2 weeks after treatment and the remainder within 1 month. Phase-inversion low-mechanical-index real-time and intermittent imaging were performed after the intravenous injection of 0.5-2 mL US contrast medium by experienced radiologists blind to all other imaging findings. Results: Nine tumors did not reach final outcome-patients were lost to follow-up or died without autopsy (n = 6) or tumors were retreated before final outcome was established (n = 3). Of the remaining 33 tumors, outcome was established by histology (n = 9), angiography (n = 14), tumor growth (n = 2), or by computed tomography and/or magnetic resonance imaging performed more than 6 months after treatment (n = 8). Twenty-three tumors were studied by CEUS within 2 weeks and 10 within 1 month after treatment. Of these 33 tumors, there were no false-negative results and one false-positive result. The only error occurred when the CEUS study was performed within 1 day after treatment. Conclusions: Residual tumor blood flow on CEUS performed at 2 or more days after transarterial chemoembolization may be predictive of tumor outcome that currently requires 3 months to be reliably detected by computed tomography and/or magnetic resonance imaging.

UR - http://www.scopus.com/inward/record.url?scp=33947718863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947718863&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2006.10.016

DO - 10.1016/j.jvir.2006.10.016

M3 - Article

C2 - 17296705

AN - SCOPUS:33947718863

VL - 18

SP - 57

EP - 65

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 1

ER -